$31.37
1.36% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Crinetics Pharmaceuticals Inc Stock price

$31.37
+1.22 4.05% 1M
-24.70 44.05% 6M
-19.76 38.65% YTD
-19.25 38.03% 1Y
+10.85 52.88% 3Y
+12.49 66.15% 5Y
+6.86 27.99% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.42 1.36%
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Key metrics

Market capitalization $2.94b
Enterprise Value $1.71b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4,763.72
P/S ratio (TTM) P/S ratio 8,163.17
P/B ratio (TTM) P/B ratio 2.34
Revenue (TTM) Revenue $360.00k
EBIT (operating result TTM) EBIT $-377.13m
Free Cash Flow (TTM) Free Cash Flow $-265.32m
Cash position $1.27b
EPS (TTM) EPS $-3.82
P/E forward negative
P/S forward 591.28
EV/Sales forward 345.05
Short interest 11.96%
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.36 0.36
-
100%
- Direct Costs 3.24 3.24
130% 130%
900%
-2.88 -2.88
104% 104%
-800%
- Selling and Administrative Expenses 111 111
71% 71%
30,889%
- Research and Development Expense 260 260
43% 43%
72,172%
-374 -374
50% 50%
-103,858%
- Depreciation and Amortization 3.24 3.24
130% 130%
900%
EBIT (Operating Income) EBIT -377 -377
51% 51%
-104,758%
Net Profit -328 -328
39% 39%
-91,181%

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
5 days ago
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients
Neutral
GlobeNewsWire
8 days ago
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and granted an aggregate of 101,800 restricted stock unit (“RSU”) awards to 35 new non-executive employees, in...
Neutral
Seeking Alpha
10 days ago
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Toby Schilke - Chief Financial Officer Conference Call Participants Yasmeen Rahim...
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 437
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today